TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04387305
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug is provided to participants as described based on the TXA arm they are randomized to.
Study: NCT05668585
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified oral dose on specified day
Study: NCT05668585
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified intravenous dose on specified day
Study: NCT00781755
Drug: varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: .5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
Study: NCT06171750
Drug: tolododekin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IT administration of ANK-101 once every 3 weeks for up to 12 weeks (4 doses); if there is no disease progression, decrease in clinical performance status or unacceptable toxicity, participants may receive 4 additional doses of ANK-101.
Study: NCT06171750
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive four cycles of ANK-101 in combination with Cemiplimab. If there is no significant clinical deterioration as determined by the Investigator or unacceptable toxicity at Week 12, participants may receive an additional four cycles of the combination treatment. After stopping ANK-101 treatment, participants may stay on Cemiplimab monotherapy for an additional 24 weeks.
Study: NCT04406818
Drug: Carbon Dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants inhale carbon dioxide while in magnetic resonance imaging scan to measure cerebrovascular reactivity
Study: NCT06006013
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05341557
Drug: BPI-371153
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BPI-371153 until disease progression
Study: NCT06495593
Drug: Ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard ocrelizumab dosing
Study: NCT05821686
Drug: Human Interleukin-2 (IL-2) (Proleukin)
Normalized name: Recombinant human interleukin-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the recruited participants will receive 4 intralesional injections of Interleukin-2 with a dose of 500,000 international units (IU) per mm width of tumor to max dose of 10 million IU.
Study: NCT04976322
Drug: Dapirolizumab pegol
Normalized name: Dapirolizumab pegol
DrugBank: Dapirolizumab pegol (DB16131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dapirolizumab pegol at prespecified time-points.
Study: NCT05960942
Drug: propofol combined with esketamine
Normalized name: esketamine
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In group PE, esketamine was firstly administered at a dose of 0.3 mg.kg-1, followed immediately by propofol with a single intravenous dose of 2.0 mg.kg-1.
Study: NCT06640166
Drug: encorafenib + cetuximab + FOLFIRI
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: encorafenib plus cetuximab beyond progression in combination with irinotecan-based doublet chemoterapy (FOLFIRI) as follows:~* encorafenib 300 mg (75 mgx4 hard capsules) orally once daily;~* cetuximab 500 mg/sqm iv every 14 days;~* FOLFIRI iv every 14 days (Irinotecan 180 mg/sqm, Folinic Acid 400 mg/sqm, 5Fluorouracil 400 mg/sqm iv bolus and 2400 mg/sqm iv continuous infusion over 46-48 hours).
Study: NCT05613218
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will have nasal cannula or oxygen mask placed as the usual standard of care.~Patients will be screened and randomized in the emergency department to either liberal or restrictive oxygenation after providing informed written consent and oxygen is titrated to the prespecified target range using an automated feedback device (O2MATIC). Consented patients will be randomly allocated to study groups via the web-based system within REDCap. The allocation will be concealed. Time at randomization will be considered as study time zero (T0). All patients will receive usual standard of care except for their O2 management. The intervention will last for 24 h. After 24 h, patients will be switched over to usual care for oxygen therapy. If the treating physician thinks, that the patient need another oxygenation target and it is thought to be harmful to continue with the allocated target, the intervention-phase can be stopped prematurely.
Study: NCT06802081
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week12 (10mg) as tolerated.
Study: NCT05083481
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Infusion
Study: NCT05083481
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Infusion
Study: NCT05083481
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT05214222
Drug: Anlotinib/Penpulimab/Chemotherapy
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (4-6 cycles): Anlotinib, Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Anlotinib: once a day, 1 capsule each time (10mg for body weight \<60KG, 12mg for body weight ≥60KG), d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Anlotinib, Penpulimab~* Anlotinib: once a day, 1 capsule each time (the same as the initial treatment dose), take the drug every cycle d1-d14, 3 weeks as a treatment cycle.~* Penpulimab: 200mg, d1 per cycle, once every 3 weeks
Study: NCT05214222
Drug: Penpulimab/Chemotherapy
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment (4-6 cycles): Penpulimab, Paclitaxel or Albumin Paclitaxel,Cisplatin~* Penpulimab: 200 mg, d1 per cycle, once every 3 weeks.~* Paclitaxel: According to 135-175mg/m2, intravenous infusion\> 2h, d1, 3 weeks as a treatment cycle; Albumin paclitaxel: According to 200-260mg/m2, intravenous infusion for 30 minutes, d1, 3 weeks as a treatment cycle.~* Cisplatin: 60-75mg/m2, intravenous infusion, divided into d1-d3 medication per cycle; 3 weeks is a treatment cycle.~Maintenance treatment: Penpulimab~• Penpulimab: 200mg, d1 per cycle, once every 3 weeks Post-progression genetic testing, continued treatment: Anlotinib,Penpulimab Anlotinib: Once daily, one capsule per time (10mg for weight \<60KG, 12mg for weight ≥60KG), administered from day 1 to day 14 of each cycle. Two consecutive weeks of treatment followed by one week off, 3 weeks per treatment cycle.~Penpulimab: 200mg, administered on day 1 of each cycle, every 3 weeks.
Study: NCT04809181
Drug: Azacitidine in Combination With Venetoclax
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine in combination with venetoclax
Study: NCT06503016
Drug: Phosphocreatine
Normalized name: Phosphocreatine
DrugBank: Phosphocreatine (DB13191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Phosphocreatine
Study: NCT05116995
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rivaroxaban 2.5 mg twice a day for 7 days
Study: NCT05116995
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 60 mg twice a day for 7 days
Study: NCT04752384
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine will be started at 5 mcg/hr once a week. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 20 mcg/hr once a week.
Study: NCT04752384
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tramadol will be started at 50 mg/day. Depending on the Visual Analog Scale (VAS) score, it may be increased up to 400 mg/day.
Study: NCT06386887
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will be given as standard treatment every 3 weeks (21 days) and continue for 3 to 4 cycles per routine care. As chemotherapy is not part of this research study, participants will begin standard chemotherapy as decided by their physician.
Study: NCT05669664
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05669664
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM
Study: NCT04707469
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive once daily semaglutide tablets (oral administration) in a dose escalating manner for 68 weeks.
Study: NCT06265688
Drug: CX-2051
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug monotherapy
Study: NCT04487860
Drug: AS012
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration
Study: NCT05212922
Drug: YH001 + Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH001 + Toripalimab
Study: NCT06518941
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication will be initiated at 1mg, to be taken before bed. Dosing will follow a flexible titration. The expected titration will be 1 mg for 2 weeks, 2.5 mg for 2 weeks, then 5 mg for 4 weeks. Doses may be lowered from those recommended by the protocol if side effects are significant.
Study: NCT06052566
Drug: Efinopegdutide
Normalized name: Efinopegdutide
DrugBank: Efinopegdutide (DB15077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection administered at a dose of 7 mg
Study: NCT05363319
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: solution for injection via intravenous (IV) infusion
Study: NCT05363319
Drug: Platinum-based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: NCT06014385
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TO will be measured following a 15-minute IV infusion of up to 2 dose levels of scopolamine: 4.0 μg/kg and 2.0 μg/kg
Study: NCT05079282
Drug: ONO-4685
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-4685 is administered by IV infusion. The administration of ONO-4685 will be continued until disease progression or unacceptable toxicity is observed
Study: NCT06540391
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: NCT05492591
Drug: Peginterferon α1b
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injecting different doses of the peginterferon α1b into different groups of subjects.
Study: NCT05492591
Drug: Peginterferon α1b with valacyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
Study: NCT05492591
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir is a positive control drug.
Study: NCT06424899
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Study: NCT06424899
Drug: Platinum based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum based chemotherapy: Platinum drug must be one of cisplatin, carboplatin or nedaplatin; The other drug must contain one of the following: etoposide, vinorelbine, vinblastine, pemetrexed, taxanes (e.g., paclitaxel, docetaxel, albumin paclitaxel, paclitaxel liposomes) or gemcitabine (gemcitabine is not permitted in concurrent chemoradiotherapy regimens).
Study: NCT04622293
Drug: Solriamfetol Oral Tablet [Sunosi]
Normalized name: solriamfetol Oral Tablet [Sunosi]
DrugBank: Solriamfetol (DB14754)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solriamfetol will be given to those participants placed in the experimental group, and given at three possible dosages ( 37.5 mg, 75 mg, and 150 mg). Solriamfetol is already FDA approved for treatment of excessive daytime sleepiness, and has been found safe to use. In this study, we are determining if solriamfetol can also be used to treat chronic fatigue syndrome.
Study: NCT05244304
Drug: Tinlarebant
Normalized name: Tinlarebant
DrugBank: Tinlarebant (DB17832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinlarebant drug substance is a white to off-white substance and is dispensed as a tablet for oral administration.
Study: NCT05004077
Drug: AMIODARONE
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Assess the effectiveness of different dosing strategies of amiodarone.
Study: NCT06547255
Drug: Bupivacaine liposome injectable suspension
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the end of the third molar extraction surgical procedure performed under general anesthesia and at least fifteen minutes following the most recent administration of 2% lidocaine with 1:100,000 epinephrine nerve block (routine for this procedure), all patients will receive bilateral infiltrations with 3mL of 1.3% liposomal bupivacaine (Exparel) OR with 3mL of 0.5% bupivacaine with 1:200,000 epinephrine while they are still under general anesthesia.
Study: NCT06413654
Drug: B001
Normalized name: KB001
DrugBank: KB001 (DB05222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will receive IV dose of B001 on Day 1 and Day 15 of RCP
Study: NCT06058156
Drug: SAR444656 (KT-474)
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Tablet
Study: NCT05689151
Drug: Abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study Drug for Observational Data Collection
Study: NCT05672472
Drug: Sivelestat sodium
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Continuous infusion of sivelestat sodium for 5 days
Study: NCT03847376
Drug: Rilpivirine Long Acting (RPV LA)
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter \[mL\] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
Study: NCT05590728
Drug: Apramycin (EBL-1003)
Normalized name: Adriamycin
DrugBank: Apramycin (DB04626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mono-substituted 2-deoxystreptamine comprising a unique bicyclic octadiose moiety. It is a crystalline free base of the amoniglycoside apramycin.
Study: NCT06536491
Drug: EC-104 high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT06536491
Drug: Dexamethasone intravitreal implant
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Marketed product intravitreal injection
Study: NCT04801966
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg per day, continuous
Study: NCT05719376
Drug: Monofer (experimental)
Normalized name: Monoferric
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monofer 200mg : OP-28day, OP-21day, OP-7day, OP day, POD #7 IV injection, Mircera 120mcg SQ : OP-7 day\~OP-1day
Study: NCT04801966
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg/day for 21 days of a 28 day cycle
Study: NCT04801966
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 45 mg/twice a day, continuous
Study: NCT04801966
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/day, continuous
Study: NCT04801966
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 960 mg/twice per day, continuous
Study: NCT04801966
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg/twicce per day, continuous
Study: NCT04801966
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 450 mg/day, continuous
Study: NCT04801966
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/day, day 1-21 of a 28 day cycle
Study: NCT04801966
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg/twice per day, continuous
Study: NCT04801966
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg/day, on day 1 -21 of a 28 day cycle
Study: NCT04801966
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg twice/day, continuous
Study: NCT04801966
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day, on day 1 -28 of each 28 day cycle
Study: NCT04801966
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg IV once every 2 weeks
Study: NCT04801966
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg IV on Day 1 of a 21 day cycle
Study: NCT04801966
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV on day 1 of a 21 day cycle
Study: NCT06356675
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg iv D1 Q3W
Study: NCT06356675
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12mg D1-12 Q3W
Study: NCT05708170
Drug: Ferinject
Normalized name: epinephrine
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferinject Therapy Group: each patient's Iron need for repletion by the Ferinject will be determined using product SPC dosing based on patient's body weight and Hb level. Accordingly, the appropriate dose of Ferinject will be administered while ensuring that a single administration will not exceed:~* 15 mg iron/kg body weight (for administration by intravenous injection) or 20 mg iron/kg body weight (for administration by intravenous infusion)~* 1,000 mg of iron (20 mL Ferinject) The cumulative dose of Ferinject per week will not exceed 1,000 mg of iron (20 mL Ferinject).
Study: NCT05708170
Drug: Ferrous Sulfate 200 MG
Normalized name: ferrous sulfate 200 MG
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Control Group (standard care excl. IV Iron): Oral Ferrous sulphate 200 mg three times daily.
Study: NCT05534945
Drug: Programmed intermittent epidural bolus 5 ml
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive a programmed epidural intermittent bolus of 5 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Study: NCT05534945
Drug: Programmed intermittent epidural bolus 6 ml
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive a programmed epidural intermittent bolus of 6 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Study: NCT04947956
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The camrelizumab-based treatment will be determined by the investigator.
Study: NCT05534945
Drug: Programmed intermittent epidural bolus 7 ml
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive a programmed epidural intermittent bolus of 7 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10
Study: NCT05534945
Drug: Programmed intermittent epidural bolus 8 ml
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in this group will receive a programmed epidural intermittent bolus of 8 mL every 60 min. Patients will also be allowed patient controlled epidural boluses of 5 ml, every 30 min, as needed to treat pain \> 4/10